CACNA1C and chronic cystitis: The broad tissue distribution of Cav1.2 is consistent with the broad spectrum of ketamine’s physiological and pathological effects, suggesting that Cav1.2 may serve as a therapeutic target not only in ketamine cystitis, but also for treatment of other smooth muscle-related adverse effects of ketamine.